11.44MMarket Cap-722P/E (TTM)
1.4762High1.3200Low10.95KVolume1.3700Open1.4500Pre Close15.55KTurnover0.23%Turnover RatioLossP/E (Static)7.92MShares5.500052wk High-49.79P/B6.90MFloat Cap1.077552wk Low--Dividend TTM4.78MShs Float5000.0000Historical High--Div YieldTTM10.77%Amplitude1.0775Historical Low1.4190Avg Price1Lot Size
Akari Therapeutics Stock Forum
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
•Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease•Akari Therapeutics announces leadership changes in separate Akari press release
BOSTON and PLEASANTON, May 1, 2024 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc ...
8 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
bottom
No comment yet